Pharma Giant GSK to Acquire US-Based Nuvalent in a Massive USD 10.6 Billion Deal

21:03 - 9.06.2026

June 9, Fineko/abc.az. The UK-based multinational pharmaceutical company GSK has officially announced an agreement to acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies.

ABC.AZ reports that the economic value of the transaction is estimated at USD 10.6 billion. Net of acquired cash assets, GSK's total net investment is calculated to stand at USD 9.4 billion.

Strategic Highlights of the Acquisition:

  • Lung Cancer Pipeline: The single transaction grants GSK control over three innovative products aimed at treating lung cancer, effectively accelerating the group's positioning in the oncology market.

  • Revenue Growth: The acquisition is projected to contribute positively to GSK’s revenue growth starting in 2027, underpinning the group's strategic roadmap to exceed USD 40 billion (over £40 billion) in sales by 2031.

  • Regulatory Approvals: The deal is anticipated to receive official clearance from the U.S. Food and Drug Administration (FDA) within the current year.